Literature DB >> 26561198

2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).

Alberto Leoni1, Alessandra Locatelli1, Rita Morigi1, Mirella Rambaldi1.   

Abstract

INTRODUCTION: 2-Indolinone is a well-known aromatic heterocyclic organic compound. A lot of work has been done on this bicyclic structure by academic and company researchers to synthesize compounds directed to a plethora of molecular targets in order to discover new drug leads. This review presents up-to-date information in the field of cancer therapy research based on this small building block. AREAS COVERED: The present review gives an account of the recent patent literature (2008-2014) describing the discovery of 2-indolinone derivatives with selected therapeutic activities. In this period, a large amount of patents were published on this topic. We have limited the analysis to 37 patents on 2-indolinone derivatives having potential clinical application as chemotherapeutic agents. In this review, the therapeutic applications of 2-indolinone derivatives for the treatment of cancer reported in international patents have been discussed. EXPERT OPINION: 2-Indolinone is the scaffold of the compounds considered from a medicinal chemistry perspective. Many of them have been developed and marketed for therapeutic use. In cancer chemotherapy, progress has been made in designing selective 2-indolinone derivatives. Some of them show preclinical efficacy. However, 2-indolinone has not exhausted all of its potential in the development of new compounds for clinical applications and remains a great tool for future research.

Entities:  

Keywords:  2-indolinone; Inhibitor; histone deacetylase; mouse double minute 2; oxindole; polo-like kinase; tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26561198     DOI: 10.1517/13543776.2016.1118059

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  6 in total

1.  KMU-1170, a Novel Multi-Protein Kinase Inhibitor, Suppresses Inflammatory Signal Transduction in THP-1 Cells and Human Osteoarthritic Fibroblast-Like Synoviocytes by Suppressing Activation of NF-κB and NLRP3 Inflammasome Signaling Pathway.

Authors:  Hye Suk Baek; Victor Sukbong Hong; Sang Hyon Kim; Jinho Lee; Shin Kim
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

2.  Substituted spirooxindole derivatives as potent anticancer agents through inhibition of phosphodiesterase 1.

Authors:  Assem Barakat; Mohammad Shahidul Islam; Hussien Mansur Ghawas; Abdullah Mohammed Al-Majid; Fardous F El-Senduny; Farid A Badria; Yaseen A M M Elshaier; Hazem A Ghabbour
Journal:  RSC Adv       Date:  2018-04-17       Impact factor: 4.036

3.  Integration of the Microbiome, Metabolome and Transcriptomics Data Identified Novel Metabolic Pathway Regulation in Colorectal Cancer.

Authors:  Vartika Bisht; Katrina Nash; Yuanwei Xu; Prasoon Agarwal; Sofie Bosch; Georgios V Gkoutos; Animesh Acharjee
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 4.  Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.

Authors:  Jyothi Dhuguru; Rachid Skouta
Journal:  Molecules       Date:  2020-04-01       Impact factor: 4.411

5.  RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa.

Authors:  Lucas Milanez Benicio; Ane Stefano Simionato; Cláudio Roberto Novello; Jeconias Rocha Guimarães; Ingrid Felicidade; Admilton Gonçalves de Oliveira; João Carlos Palazzo de Mello; Mário Sérgio Mantovani; Andreas Lazaros Chryssafidis; Galdino Andrade; Ilce Mara de Syllos Colus; Marcelo Tempesta de Oliveira
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

6.  Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway.

Authors:  Hye Suk Baek; Hyeon Ji Min; Victor Sukbong Hong; Taeg Kyu Kwon; Jong Wook Park; Jinho Lee; Shin Kim
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.